Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines
ChemistryOpen · 2025-08 · 14 (8)
DOI: 10.1002/open.202400518 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistryOpen, online erschienen am 05.02.2025. Verfasst von Gabriele La Monica und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 17, I-901…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Quinolines, Drug Design, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SiciliAn MicronanOTecH Research and Innovation Center "SAMOTHRACE", SPOKE 3-Università degli Studi di Palermo, S2-COMMs-Micro and Nanotechnologies for Smart & Sustainable Communities and National Biodiversity Future Center.
Abstract (Originalsprache)
In the search for new anticancer compounds, quinoline and piperazine moieties represent the most promising pharmacophoric fragments for the development of more effective drugs. A particularly interesting approach in medicinal chemistry is molecular hybridization, where different known components are integrated into a single chemical entity, resulting in hybrid molecules with enhanced biological activity. In this study, we have developed a new series of 4‐(4‐benzoylpiperazin‐1‐yl)‐6‐nitroquinoline‐3‐carbonitrile compounds ( 8 a – l ), with potential anticancer effect, by combining the quinoline, the piperazinyl and the benzoylamino moieties. The rationalized compounds ( 8 a – l ) were first evaluated in silico to assess the ADMET and drug‐likeness profiles, synthesized using appropriate synthetic strategies and then tested in vitro under the National Cancer Institute DTP‐NCI60 program. The entire series exhibited potent anticancer activity against the renal cell carcinoma (RCC) cell line UO‐31, with compounds 8 c and 8 g effectively inhibiting cancer cell growth without excessive cytotoxic effects (growth percentages of −7 and −19, respectively). In silico induced fit docking (IFD) and molecular dynamics (MD) studies provided further insights into the putative mechanisms of action for both compounds, which were predicted to strongly bind key oncogenic proteins involved in RCC progression. The promising in vitro and in silico results herein presented provide a solid foundation for the development of a new series of small heterocyclic molecules with anticancer activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 17, I-90128, Palermo, Italy.
ORCID-Profile: Gabriele La Monica, Alessia Bono, Federica Alamia, Annamaria Martorana, Antonino Lauria
Förderung
- SiciliAn MicronanOTecH Research and Innovation Center "SAMOTHRACE"
- SPOKE 3-Università degli Studi di Palermo
- S2-COMMs-Micro and Nanotechnologies for Smart & Sustainable Communities and National Biodiversity Future Center
Zitieren
APA
La Monica, G., Bono, A., Alamia, F., Martorana, A., & Lauria, A. (2025). Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines. ChemistryOpen, 14(8). https://doi.org/10.1002/open.202400518
Vancouver
La Monica G, Bono A, Alamia F, Martorana A, Lauria A. Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines. ChemistryOpen. 2025;14(8). doi:10.1002/open.202400518
BibTeX
@article{LaMonica2025,
author = {La Monica, Gabriele and Bono, Alessia and Alamia, Federica and Martorana, Annamaria and Lauria, Antonino},
title = {Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines},
journal = {ChemistryOpen},
year = {2025},
volume = {14},
number = {8},
doi = {10.1002/open.202400518}
}
EUVIMED